184 related articles for article (PubMed ID: 22316446)
1. Sources of regional variation in Medicare Part D drug spending.
Donohue JM; Morden NE; Gellad WF; Bynum JP; Zhou W; Hanlon JT; Skinner J
N Engl J Med; 2012 Feb; 366(6):530-8. PubMed ID: 22316446
[TBL] [Abstract][Full Text] [Related]
2. Pharmaceutical Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries.
DeJong C; Aguilar T; Tseng CW; Lin GA; Boscardin WJ; Dudley RA
JAMA Intern Med; 2016 Aug; 176(8):1114-1122. PubMed ID: 27322350
[TBL] [Abstract][Full Text] [Related]
3. Prescription Drug Spending in Fee-for-Service Medicare, 2008-2019.
Dusetzina SB; Huskamp HA; Qin X; Keating NL
JAMA; 2022 Oct; 328(15):1515-1522. PubMed ID: 36255428
[TBL] [Abstract][Full Text] [Related]
4. Brand-name prescription drug use among Veterans Affairs and Medicare Part D patients with diabetes: a national cohort comparison.
Gellad WF; Donohue JM; Zhao X; Mor MK; Thorpe CT; Smith J; Good CB; Fine MJ; Morden NE
Ann Intern Med; 2013 Jul; 159(2):105-14. PubMed ID: 23752663
[TBL] [Abstract][Full Text] [Related]
5. Prescription Drug Spending and Medication Adherence Among Medicare Beneficiaries with Heart Failure.
McGee BT; Phillips V; Higgins MK; Butler J
J Manag Care Spec Pharm; 2019 Jun; 25(6):705-713. PubMed ID: 31134861
[TBL] [Abstract][Full Text] [Related]
6. ACE Inhibitor and ARB utilization and expenditures in the Medicaid fee-for-service program from 1991 to 2008.
Bian B; Kelton CM; Guo JJ; Wigle PR
J Manag Care Pharm; 2010; 16(9):671-9. PubMed ID: 21067253
[TBL] [Abstract][Full Text] [Related]
7. Factors Associated With Prescriptions for Branded Medications in the Medicare Part D Program.
Socal MP; Bai G; Anderson GF
JAMA Netw Open; 2021 Mar; 4(3):e210483. PubMed ID: 33651110
[TBL] [Abstract][Full Text] [Related]
8. Prostaglandin Coverage and Costs to Medicare and Medicare Beneficiaries, 2009-2017.
Bartlett VL; Liu P; Dhruva SS; Shah ND; Bollinger KE; Ross JS
J Manag Care Spec Pharm; 2020 Apr; 26(4):562-567. PubMed ID: 32223594
[TBL] [Abstract][Full Text] [Related]
9. Trends in Utilization and Cost of Low-Density Lipoprotein Cholesterol-Lowering Therapies Among Medicare Beneficiaries: An Analysis From the Medicare Part D Database.
Sumarsono A; Lalani HS; Vaduganathan M; Navar AM; Fonarow GC; Das SR; Pandey A
JAMA Cardiol; 2021 Jan; 6(1):92-96. PubMed ID: 32902560
[TBL] [Abstract][Full Text] [Related]
10. Drug Expenditure, Price, and Utilization in the U.S. Medicaid: A Trend Analysis for SSRI and SNRI Antidepressants from 1991 to 2018.
Alrasheed M; Hincapie AL; Guo JJ
J Ment Health Policy Econ; 2021 Mar; 24(1):3-11. PubMed ID: 33739932
[TBL] [Abstract][Full Text] [Related]
11. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
[TBL] [Abstract][Full Text] [Related]
12. Regional variation in Medicare Part D drug spending.
Flansbaum B
N Engl J Med; 2012 May; 366(19):1842; author reply 1842-3. PubMed ID: 22571215
[No Abstract] [Full Text] [Related]
13. Regional variation in Medicare Part D drug spending.
Mukherjee D; Mukherjee C
N Engl J Med; 2012 May; 366(19):1842; author reply 1842-3. PubMed ID: 22571214
[No Abstract] [Full Text] [Related]
14. A comparison of costs of Medicare Part D prescriptions dispensed at retail and mail order pharmacies.
Carroll NV
J Manag Care Spec Pharm; 2014 Sep; 20(9):959-67. PubMed ID: 25166295
[TBL] [Abstract][Full Text] [Related]
15. Variation in Prescription Drug Coverage Enrollment Among Vulnerable Beneficiaries With Glaucoma Before and After the Implementation of Medicare Part D.
Blumberg DM; Prager AJ; Liebmann JM
JAMA Ophthalmol; 2016 Feb; 134(2):212-20. PubMed ID: 26720853
[TBL] [Abstract][Full Text] [Related]
16. Impacts of generic competition and benefit management practices on spending for prescription drugs: evidence from Medicare's Part D benefit.
Sheingold S; Nguyen NX
Medicare Medicaid Res Rev; 2014; 4(1):. PubMed ID: 24918023
[TBL] [Abstract][Full Text] [Related]
17. The Effect of Medicare Part D on Prescription Drug Spending and Health Care Use: 6 Years of Follow-up, 2007-2012.
Park T; Jung J
J Manag Care Spec Pharm; 2017 Jan; 23(1):5-12. PubMed ID: 28025927
[TBL] [Abstract][Full Text] [Related]
18. Private expenditures on brand name prescription drugs after generic entry.
Balaban DY; Dhalla IA; Law MR; Bell CM
Appl Health Econ Health Policy; 2013 Oct; 11(5):523-9. PubMed ID: 23979876
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance.
DiStefano MJ; Kang SY; Parasrampuria S; Anderson GF
JAMA Health Forum; 2023 May; 4(5):e231090. PubMed ID: 37234016
[TBL] [Abstract][Full Text] [Related]
20. Effects of Medicare Part D on drug affordability and use: Are seniors with prior high out-of-pocket drug spending affected more?
Mott DA; Thorpe JM; Thorpe CT; Kreling DH; Gadkari AS
Res Social Adm Pharm; 2010 Jun; 6(2):90-9. PubMed ID: 20511108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]